Physician profile
Samuel K Suttle
NPI 1497705453
$5,051.87
in general payments reported to CMS, 2019-2025
24 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $786 · 2021: $810 · 2022: $715 · 2023: $466 · 2024: $606 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.15 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,617.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,167.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $408.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $299.26 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.73 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $245.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $227.46 | 2019-2022 | |
| Abbott Laboratories | $133.57 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $121.45 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $118.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $101.99 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.92 | 2019-2020 | |
| Pfizer INC. | $37.93 | 2019-2020 | |
| Glaxosmithkline, LLC. | $34.33 | 2019-2023 | Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.88 | 2023 | Vraylar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.77 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.47 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.98 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.98 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $12.85 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.41 | 2022 | |
| Sanofi Pasteur INC. | $12.17 | 2019 | |
| Grifols USA, LLC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Suttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.